Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 188 от 222

Набира участници Фаза 1

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

Renal Cell Carcinoma (RCC) Metastatic Castration-Resistant Prostate Cancer (mCRPC) Urothelial Carcinoma (UC) Solid Tumor +6

This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alone, and in combination with nivolumab (doublet), nivolumab + ipilimumab (triplet) and nivolumab + relatlimab (triplet) in participants with advanced solid tumors. In the Expansion Stage, the safety and efficacy of zanzalintinib as monotherapy and in combination therapy will be further evaluated in tumor-specific Expansion Cohorts.

Начало: 14.12.2021 Край: 28.06.2030 Възраст: от 18 г. Лечение

Australia, Belgium, France +9 Exelixis NCT05176483

Набира участници Фаза 1

A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)

Adult Glioblastoma High Grade Glioma WHO Grade III or IV Malignant Glioma

The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in (Stratum 1) adult patients with newly diagnosed GBM (MGMT low level or unmethylated in adults only) and (Stratum 2) in pediatric patients with newly diagnosed HGG (pHGG). Funding Source - FDA OOPD

Начало: 13.12.2021 Край: 01.07.2029 Възраст: от 4 г.

United States University of Florida NCT04573140

Набира участници

The Severe Von Willebrand Disease (sVWD) Patient Registry

VWD - Von Willebrand's Disease

A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD). Data will be self-reported by patients and/or collected by registry personnel, as appropriate. The purpose of the sVWD Patient Registry is to create a database of well-characterized (with respect to demographics, medical history, symptoms, laboratory and genetic data, etc.) patients with sVWD for participation in retrospective and prospective research.

Начало: 10.12.2021 Край: 01.12.2031

United States VWD Connect Foundation NCT05437536

Набира участници

Stress Phenotypes and Preterm Birth

Preterm Birth Inflammation Stress Mental Health Issue

Pregnancy ends in preterm birth (PTB) for approximately 1 in 10 women, though more often for Non-Hispanic Black women, 14.12% PTB rate, compared to 9.09% for Non-Hispanic White women. Psychosocial stress and childhood trauma each are associated with risk for PTB and PTB has an intergenerational impact: mothers born preterm are more likely to give birth preterm, especially amongst Black women. In this project, we will study mitochondria, which contain their own genome, the mitochondria DNA, and are inherited from the mother, as they represent a potential intersection point between psychosocial experiences and their biological embedding in underlying disease outcomes such as PTB

Начало: 09.12.2021 Край: 01.12.2027 Възраст: от 18 г.

United States Columbia University NCT05229666

Набира участници Фаза 1

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours

Neuroendocrine Tumors

This phase 1 dose-escalation study is designed to evaluate the safety and tolerability of talazoparib in combination with 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) in patients with metastatic pancreatic or midgut neuroendocrine tumour (NET).

Начало: 08.12.2021 Край: 30.06.2029 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT05053854

Набира участници Фаза 2

A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study

Esophageal Cancer

The purpose of this study is to investigate the effects of the addition of the stereotactic body radiotherapy and durvalumab to a well tolerated 2 week chemotherapy and radiation treatment regimen in people with esophageal cancer that is locally advanced or has spread to another area of the body (metastasized).

Начало: 08.12.2021 Край: 31.07.2029 Възраст: от 18 г. Лечение

Australia, New Zealand Australasian Gastro-Intestinal Trials Group NCT06290505

Набира участници Фаза 1

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

PIK3CA Mutation Solid Tumor, Adult HER2-negative Breast Cancer Breast Cancer +3

This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors. It will also evaluate RLY-2608 in combination RLY-2608 + fulvestrant and in triple combination RLY-2608 + fulvestrant + CDK4/6 inhibitor (palbociclib or ribociclib) or CDK4 inhibitor (PF-07220060) for patients with HR+ HER2- locally advanced or metastatic breast cancer. The RLY-2608 single agent arm, RLY-2608 + fulvestrant combination arm, and triple combination arms will have 2 parts: a dose escalation (Part 1) and a dose expansion (Part 2).

Начало: 08.12.2021 Край: 30.04.2027 Възраст: от 18 г. Лечение

Australia, France, Italy +2 Relay Therapeutics, Inc. NCT05216432

Набира участници Фаза 3

A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures

Stereotypical Prolonged Seizures

The purpose of the study is to assess the success of a single administration of Staccato alprazolam compared with placebo both in rapidly terminating a seizure episode within 90 seconds and with no recurrence of seizure(s) up to 2 hours after investigational medicinal product (IMP) administration.

Начало: 07.12.2021 Край: 01.04.2026 Възраст: от 12 г. Лечение

Australia, Bulgaria, China +10 UCB Biopharma SRL NCT05077904

Набира участници Фаза 2

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Peripheral Blood Stem Cell Transplantation

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.

Начало: 01.12.2021 Край: 01.06.2031 Възраст: 12–65 г.

China Chinese PLA General Hospital NCT05088226

Набира участници

Exercise Therapy for PAD Using Mobile Health

Peripheral Artery Disease

Peripheral artery disease (PAD) is a highly prevalent condition affecting up to 10% of Veterans that leads to loss of walking ability and increased risk of amputation. Veterans have limited access to supervised exercise therapy, a facility-based program proven to improve walking ability in PAD, which is poorly attended due to the inconvenience and cost of attending a 12-week program with multiple weekly sessions. This CDA-2 application will investigate the feasibility of home-based exercise therapy (HBET) delivered using mobile health (mHealth) technologies in Veterans with symptomatic PAD. We will partner with the MOVE! program to deliver HBET through group behavioral coaching and a novel wearable activity monitor in a newly proposed program called Smart MOVE!. There is a clear need to provide effective and convenient alternatives to supervised exercise for Veterans with PAD. This study will provide evidence to proceed with Smart MOVE!, a much-needed patient-centered rehabilitation program for Veterans with PAD.

Начало: 01.12.2021 Край: 30.09.2026 Възраст: от 40 г.

United States VA Office of Research and Development NCT04889105

Набира участници

The Use of Remote Monitoring for Orthodontic Retention Review

Orthodontic Relapse

To assess whether using retainers and an artificial intelligence supported remote monitoring system maintains a more stable orthodontic treatment result than using retainers with in-office review appointments.

Начало: 01.12.2021 Край: 22.09.2025 Възраст: от 12 г. Превенция

Australia Sydney Local Health District NCT05006339

Набира участници

Functional Lung Avoidance SPECT-guided Radiation Therapy of Lung Cancer

Lung Cancer Radiation-Induced Disorder Radiation Pneumonitis Pulmonary Disease +1

Study aims to determine if functional lung avoidance based on perfusion single photon emission (SPECT)/CT scan, improves toxicity outcomes for patients with advanced lung cancer undergoing chemo-radiotherapy. Functional avoidance implies a dose plan that takes functional distribution in the lung into account, and avoids highly functional lung volumes sparing them from radiation.

Начало: 01.12.2021 Край: 01.12.2028 Възраст: от 18 г. Лечение

Australia, Denmark University of Aarhus NCT04676828

Набира участници

The National Australian HCV Point-of-Care Testing Program - Minimal Dataset

Hepatitis C

The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.

Начало: 01.12.2021 Край: 01.12.2026 Възраст: от 18 г.

Australia Kirby Institute NCT05248555

Набира участници Фаза 2/3

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis Smoldering Systemic Mastocytosis

This is a randomized, double-blind, placebo-controlled, Phase 2/3 study comparing the efficacy and safety of elenestinib (BLU-263) + symptom directed therapy (SDT) with placebo + SDT in participants with indolent systemic mastocytosis (ISM) whose symptoms are not adequately controlled by SDT. Parts 1 and 2 will enroll participants with ISM. Participants enrolled in Part 2 will roll over onto Part 3 to receive treatment with elenestinib in an open-label fashion following completion of the earlier Part. Part K will enroll participants with ISM who have previously received an approved selective KIT inhibitor. The study also includes pharmacokinetic (PK) groups that will enroll participants with ISM.

Начало: 30.11.2021 Край: 30.09.2032 Възраст: от 18 г. Лечение

Argentina, Australia, Austria +15 Blueprint Medicines Corporation NCT04910685

Набира участници Фаза 1/2

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Neurofibromatosis 1

Background: NF1 is a genetic disease that causes tumors called atypical neurofibromas. These tumors, which arise from nerves, can cause serious medical problems. The only treatment is surgery. Researchers want to see if a drug called abemaciclib can help. Objective: To find a safe, tolerable dose of abemaciclib for treating atypical neurofibromas. Eligibility: People ages 12 and older who have NF1 and have one or more atypical neurofibromas that cannot or will not be removed with surgery Design: Participants will be screened with: Medical history and physical exam Blood, urine, and heart tests MRI: Participants will lie in a machine that takes pictures of the body. A padding or coil will be placed around their head. They may have a contrast agent injected into a vein. Biopsy sample: A small piece of tumor will be removed using a large needle. Participants will have frequent visits during the study. These will include repeats of the screening tests as well as the following: PET scan: Participants will lie in a machine that takes pictures of the body. They will have a contrast agent injected into their arm. Questionnaires about the effects of abemaciclib on pain and quality of life Possible photographs of tumors Participants will take abemaciclib capsules orally twice daily in 28-day cycles. They will take the drug for up to 2 years. Some may be able to take it for longer. Participants will have a follow-up visit about 30 days after their last dose of the study drug. Then they will have visits every 3 months for 1 year.

Начало: 29.11.2021 Край: 31.12.2029 Възраст: от 12 г.

United States National Cancer Institute (NCI) NCT04750928

Набира участници Фаза 2/3

Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

Basilar Artery Occlusion

Patients presenting to the emergency department with an acute ischemic stroke due to basilar artery occlusion within 24 hours of stroke onset will be assessed to determine their eligibility for randomization into the trial. If the patient gives informed consent they will be randomised 50:50 using a central computerised allocation process to either standard of care (no intravenous thrombolytic treatment or intravenous alteplase 0.9mg/kg) or tenecteplase 0.25mg/kg before undergoing mechanical thrombectomy as required at treating clinician's discretion. The trial is Multi-arm, Multi-stage, prospective, randomised, open-label, blinded endpoint (PROBE) design with seamless phase 2b/3 transition if the intermediate endpoint (recanalization without symptomatic intracerebral hemorrhage) is met in analysis of the first 202 patients. Adaptive sample size re-estimation (Mehta and Pocock) will be performed when 240 patients have completed 3 month follow-up (minimum sample size 320, maximum sample size 688).

Начало: 29.11.2021 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia University of Melbourne NCT05105633

Набира участници Фаза 1/2

Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)

MDS/MPN

ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test novel treatment combinations in MDS/MPN. Each Arm of AM-001 will test an active myeloid target compound in combination with ASTX727, an oral drug combining fixed doses of the DNA methyltransferase inhibitor (DNMTi) decitabine and the cytidine deaminase inhibitor E7727, also known as cedazuridine in a single tablet.

Начало: 24.11.2021 Край: 01.12.2027 Възраст: от 18 г.

United States Michael Savona NCT04061421

Набира участници

Virtual Walking Intervention for Neuropathic Pain in Spinal Cord Injury

Spinal Cord Injuries Neuropathic Pain

The purpose of this study is to determine if playing a virtual reality walking game can help improve neuropathic pain in adults with chronic spinal cord injury.

Начало: 23.11.2021 Край: 01.09.2026 Възраст: от 18 г. Лечение

Australia, United States Texas A&M University NCT05005026

Набира участници

HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial

Hip Fractures Myocardial Injury

The HIP ATTACK-2 trial is a multicentre, international, parallel group randomized controlled trial to determine whether accelerated surgery for hip fracture in patients with acute myocardial injury is superior to standard care in reducing death at 90 days after randomization. The trial will also assess secondary outcomes at 90 days after randomization: inability to independently walk 3 metres, time to first mobilization (first standing and first full weight bear), composite and individual assessment of major complications (e.g., mortality, non-fatal myocardial infarction, acute congestive heart failure, and stroke), delirium, length of stay, pain, and quality of life.

Начало: 22.11.2021 Край: 31.05.2027 Възраст: от 45 г. Лечение

Australia, Belgium, Brazil +15 Population Health Research Institute NCT04743765

Набира участници

Effect of Chitodex Gel in Tympanoplasty Surgery

Tympanic Membrane Perforation Tympanic Membrane Inflammation Surgery Otitis Media

The general purpose of this study is to compare Chitosan-dextran (Chitodex) gel versus current standard of care, Gelfoam, as a middle ear (ME) and external auditory canal (EAC) packing agent as part of tympanoplasty, ossiculoplasty and mastoidectomy procedures.

Начало: 20.11.2021 Край: 13.05.2025 Възраст: от 18 г. Лечение

Australia Central Adelaide Local Health Network Incorporated NCT06260618

1 … 186 187 188 189 190 … 222